ReviewHuman vaccines & immunotherapeutics2019
The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity.
Review in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 37 citations in OpenAlex.
- Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.Frontiers in immunology · 2022Trial
- Immunogenicity and safety of high-dose versus double-dose quadrivalent inactivated influenza vaccine in adult kidney transplant recipients: a randomized controlled trial (2023).The Lancet regional health. Southeast Asia · 2026Article
- Transdermal Delivery of an mRNA-Liposome Vaccine via Dissolving Microneedle to Preserve Vaccine Activity and Enhance Immune Activation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- The nanoemulsion adjuvant provides antigen dose-sparing effects and enhances maternal passive immune protection for the cell-cultured quadrivalent influenza virus subunit vaccine.Virology journal · 2026Article
- Safety and Immunogenicity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, Co-Administered with FluarixVaccines · 2025Article
- The case for development of a core outcome set (COS) and supplemental reporting guidelines for influenza vaccine challenge trial research in swine.Frontiers in veterinary science · 2025Article
- Article
- Article
- Review
- Article
- Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses.Vaccines · 2023Review
- Flow cytometry as an integrative method for the evaluation of vaccine immunogenicity: A validation approach.Biochemistry and biophysics reports · 2023Article
- Article
- A Novel Neuraminidase Virus-Like Particle Vaccine Offers Protection Against Heterologous H3N2 Influenza Virus Infection in the Porcine Model.Frontiers in immunology · 2022Article
- Human influenza virus challenge identifies cellular correlates of protection for oral vaccination.Cell host & microbe · 2021Article
- COVID-19 related interdisciplinary methods: Preventing errors and detecting research opportunities.Methods (San Diego, Calif.) · 2021Review
- Article
- Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review.Frontiers in immunology · 2021Review
- Hemagglutination Inhibition (HAI) antibody landscapes after vaccination with H7Nx virus like particles.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza vaccines are a fundamental tool for preventing the disease and reducing its consequences, particularly in specific high-risk groups. In order to be licensed, influenza vaccines have to meet strict criteria established by European Medicines Agency. Although the licensure of influenza vaccines started 65 years ago, Hemagglutination Inhibition and Single Radial Hemolysis are the only serological assays that can ascertain correlates of protection. However, they present evident limitations. The present review focuses on the evaluation of cell-mediated immunity (CMI), which plays an important role in the host immune response in protecting against virus-related illness and in the establishment of long-term immunological memory. Although correlates of protection are not currently available for CMI, it would be advisable to investigate this kind of immunological response for the evaluation of next-generation vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.